中文 English

OncoAim® Lung Cancer Targeting Gene Detection Assay

Detection method

The next-generation sequencing (NGS) used in this assay, compared to PCR and Sanger sequencing methods, is able to simultaneously detect mutations in the full coding sequence of multiple genes.

Test significance

This assay provides guidance for targeted treatment related to mutations, insertions/deletions, amplification, and fusions in non-small cell lung cancer.

Product advantage

- Comprehensive: Detection of all exons and variants of 12 genes using ddCAP technology. Simultaneous detection of SNVs, Indels, CNVs and Fusions. 

- Precise: Accurately locates the gene sites of targeted drugs for lung cancer and meets the requirements of clinical diagnosis and treatment. 

- Standard: Sequencing depth of at least 1,000X; targeted gene coverage up to 99.89%.

Detection of genes

Tumor genes(12)

  • ALK
  • BRAF
  • ERBB2
  • EGFR
  • FGFR1
  • MET
  • KRAS
  • NRAS
  • PIK3CA
  • TP53
  • RET
  • ROS1

Applicable to cancer patients

- Cancer patients receiving targeted therapy, in order to identify patients who will benefit most from a specific targeted drug.

- Explore the cause and mechanism of drug resistance in patients with disease progression. 

- Adjust treatment options for patients with lung cancer who failed multiline treatment.

Test procedure

*Product is for research use only.